<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>That non-rheumatic <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> is an independent risk factor for <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> has not been established with certainty </plain></SENT>
<SENT sid="1" pm="."><plain>The rationale underlying contemporary clinical trials of <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy for the prevention of <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients who have non-rheumatic <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> is that the majority of <z:hpo ids='HP_0001297'>strokes</z:hpo> in such patients are due to cardiogenic <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, there is evidence to suggest that the increased probability of <z:hpo ids='HP_0001297'>stroke</z:hpo> attributed to this <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> is due to its association with other risk factors such as <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The question of who should be anticoagulated is a major public health issue since <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> is present in approximately ten per cent of the general population aged 65 or more years </plain></SENT>
</text></document>